Axsome Therapeutics, Inc.

This study tested the long-term safety and effectiveness of AXS-12 in 68 people with narcolepsy who experience sudden muscle weakness (cataplexy) and severe daytime sleepiness. Participants had already completed an earlier study of the same drug. The goal was to see if AXS-12 can…

This study tested a new drug called AXS-07 (a mix of meloxicam and rizatriptan) for treating migraine attacks in adults who had already tried an oral CGRP inhibitor without success. About 100 people took part in this open-label Phase 3 trial. The goal was to see if the drug could…

This study tested an experimental drug called AXS-05 to see if it can safely reduce agitation in people with Alzheimer's disease. About 408 participants took either the drug or a placebo for several weeks. The goal was to measure changes in agitation using a standard rating scale…

This study tested a new oral medicine, AXS-07, for quickly stopping migraine headaches in adults. 302 people took either the study drug or a placebo pill at the start of a migraine. The main goals were to see if the drug could make headache pain go away within 2 hours and also re…

This study looked at the long-term safety and effectiveness of a drug called AXS-05 for treating agitation in people with Alzheimer's disease. 456 participants who had already been in earlier studies took the drug, and some later switched to a placebo to see if agitation symptoms…

This study tested whether solriamfetol, a medication for excessive daytime sleepiness, can also improve cognitive function (like memory and attention) in adults with obstructive sleep apnea who still feel sleepy and have trouble thinking clearly. 59 participants took either the d…

This Phase 3 trial tested whether solriamfetol, a drug already used for sleep disorders, can safely improve mood in adults with major depression. 346 participants received either the drug or a placebo. Researchers measured depression symptoms and side effects to see if this appro…

This study tested a drug called solriamfetol in 516 adults with ADHD to see if it reduces symptoms. Participants took the drug or a placebo for 6 weeks, and researchers measured changes in ADHD symptoms using a standard rating scale. The goal was to find a new treatment option fo…